Your browser doesn't support javascript.
loading
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry.
Boucly, Athénaïs; Weatherald, Jason; Savale, Laurent; de Groote, Pascal; Cottin, Vincent; Prévot, Grégoire; Chaouat, Ari; Picard, François; Horeau-Langlard, Delphine; Bourdin, Arnaud; Jutant, Etienne-Marie; Beurnier, Antoine; Jevnikar, Mitja; Jaïs, Xavier; Simonneau, Gérald; Montani, David; Sitbon, Olivier; Humbert, Marc.
Afiliação
  • Boucly A; Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.
  • Weatherald J; Dept of Respiratory and Intensive Care Medicine, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Savale L; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • de Groote P; Both authors contributed equally.
  • Cottin V; University of Calgary, Dept of Medicine, Division of Respirology, and Libin Cardiovascular Institute, Calgary, AB, Canada.
  • Prévot G; Both authors contributed equally.
  • Chaouat A; Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.
  • Picard F; Dept of Respiratory and Intensive Care Medicine, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Horeau-Langlard D; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
  • Bourdin A; Université de Lille, Service de Cardiologie, CHU Lille, Institut Pasteur de Lille, Inserm U1167, Lille, France.
  • Jutant EM; Université Lyon 1, INRAE, UMR754, IVPC, National Reference Centre for Rare Pulmonary Diseases, Hospices Civils de Lyon, Lyon, France.
  • Beurnier A; CHU de Toulouse, Hôpital Larrey, Service de Pneumologie, Toulouse, France.
  • Jevnikar M; Inserm UMR_S1116, Faculté de Médecine de Nancy, Université de Lorraine, Département de Pneumologie, CHRU de Nancy, Vandoeuvre-lès-Nancy, France.
  • Jaïs X; Université Bordeaux, Hôpital Cardiologique du Haut-Lévêque, Heart Failure Unit and Pulmonary Hypertension Expert Centre, Bordeaux, France.
  • Simonneau G; CHU de Nantes, Hôpital Laënnec, Service de Pneumologie, Nantes, France.
  • Montani D; Université Montpellier, CHU Montpellier, Dept of Respiratory Diseases, Montpellier, France.
  • Sitbon O; Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.
  • Humbert M; Dept of Respiratory and Intensive Care Medicine, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Eur Respir J ; 59(6)2022 06.
Article em En | MEDLINE | ID: mdl-34737227
INTRODUCTION: Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate risk. Our aim was to validate a four-stratum risk assessment approach categorising patients as low, intermediate-low, intermediate-high or high risk, as proposed by the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) investigators. METHODS: We evaluated incident patients from the French PAH Registry and applied a four-stratum risk method at baseline and at first reassessment. We applied refined cut-points for three variables: World Health Organization functional class, 6-min walk distance and N-terminal pro-brain natriuretic peptide. We used Kaplan-Meier survival analyses and Cox proportional hazards regression to assess survival according to three-stratum and four-stratum risk approaches. RESULTS: At baseline (n=2879), the four-stratum approach identified four distinct risk groups and performed slightly better than a three-stratum method for predicting mortality. Four-stratum model discrimination was significantly higher than the three-stratum method when applied during follow-up and refined risk categories among subgroups with idiopathic PAH, connective tissue disease-associated PAH, congenital heart disease and portopulmonary hypertension. Using the four-stratum approach, 53% of patients changed risk category from baseline compared to 39% of patients when applying the three-stratum approach. Those who achieved or maintained a low risk status had the best survival, whereas there were more nuanced differences in survival for patients who were intermediate-low and intermediate-high risk. CONCLUSIONS: The four-stratum risk assessment method refined risk prediction, especially within the intermediate risk category of patients, performed better at predicting survival and was more sensitive to change than the three-stratum approach.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hipertensão Arterial Pulmonar / Hipertensão Pulmonar Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hipertensão Arterial Pulmonar / Hipertensão Pulmonar Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França